QURE uniQure N.V.

~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington's disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory...

uniQure N.V. ( NASDAQ:QURE ) shares have had a horrible month, losing 29% after a relatively good period beforehand...